
Cardiff Oncology, a biotech firm in California, specializes in developing cancer treatments.
Cardiff Oncology, founded in California, is a clinical-stage biotechnology company focused on developing innovative cancer treatments. Their core mission is to leverage PLK1 inhibition to create novel therapies for various cancers, addressing significant unmet medical needs. The company's flagship product, onvansertib, is a PLK1 inhibitor currently being evaluated in combination with standard-of-care therapeutics in clinical programs targeting solid tumors and hematologic cancers.
Notable figures associated with Cardiff Oncology include experienced biotech executives and leading oncology researchers. The company has attracted investment from prominent biotech venture capital firms, which has enabled significant advancements in their clinical programs. Cardiff Oncology's key achievements include promising clinical trial results for onvansertib, demonstrating potential efficacy in difficult-to-treat cancers. Their work has had a substantial impact on the oncology field, offering hope for more effective cancer treatments.

Clovis Oncology

Oncternal Therapeutics
oncternal.com

Traws Pharma

Cullinan Oncology

OncoTartis

OncoSpherix
oncospherix.com

Vivacitas Oncology
vivaoncology.com

Champions Oncology

Oncolix

OncoPrecision
oncoprecision.bio

Immune-Onc Therapeutics
immuneonc.com

Western Oncolytics

OncoSenX
oncosenx.com

Oncofactor
oncofactor.com

Cancervax
cancervax.com
Companies similar to Cardiff Oncology include Clovis Oncology, Oncternal Therapeutics, Traws Pharma and Cullinan Oncology.
Cardiff Oncology was founded in 1999.
Cardiff Oncology's headquarters is located in San Diego, CA, US.
Cardiff Oncology's most recent funding round was for $15M (USD) in November 2021.
As of Nov 18, 2021, Cardiff Oncology has raised a total of $80.5M (USD).
Cardiff Oncology has 26 employees as of Feb 6, 2024.